COMPANY:

A3P Biomedical

"A3P Biomedical and Labor Dr. Wisplinghoff, one of Germany's largest and most renowned medical laboratories, are excited to announce that Stockholm3, for early detection of prostate cancer, has now been launched and is available in Germany."

"Stockholm3 has been independently, externally validated at the Martini Klinik, the world-renowned prostate cancer center in Hamburg, Germany. The Martini validation study demonstrated results consistent with previous Stockholm3 studies, achieving a 52 percent reduction of unnecessary biopsies."

"Findings from the SEPTA trial demonstrate the utility and generalizability of Stockholm3 in reducing unneeded biopsies and detecting prostate cancer (PCa) in Asian, Black, Hispanic, and White men, representing an important improvement in the harm-benefit tradeoffs in PCa detection."

"A3P Biomedical AB...and BioAgilytix...are excited to announce that Stockholm3 for early detection of prostate cancer is now commercially available as a Lab Developed Test (LDT) throughout the United States."

"A recent study published in European Urology Open Science demonstrates that incorporating Stockholm3 into prostate cancer diagnostics can significantly reduce healthcare costs. Stockholm3, which combines genetic-, protein- and clinical markers, also provides a more accurate risk stratification for developing significant prostate cancer compared to PSA testing alone."

"The annual 2024 European Association of Urology (EAU) meeting was held in Paris from April 5 – 8. More sophisticated risk adapted prostate cancer strategies was a focus area, including six abstracts evaluating Stockholm3 in populations across Europe and North America. An abstract utilizing a baseline Stockholm3 score to predict biochemical recurrence after prostatectomy was awarded best abstract in the prostate cancer biopsy indication session."

"In 2002, Region Stockholm and Region Gotland (the Region) began a joint three-year project by offering organised prostate cancer testing (OPT) to all 50-year-old men living in the Region. In 2024, an evaluation of the Stockholm3 test will be made in a research project at Karolinska Institutet in collaboration with OPT."

"In the latest edition of European Urology Open Sciences, the Prostate Cancer Center at Capio St. Göran’s Hospital is highlighted for its well-invested and structured model for prostate cancer diagnostics. This model, based on Stockholm3 combined with MRI and targeted biopsies has been shown to significantly improve the diagnostic outcome and health economics."

"The primary results of the landmark SEPTA trial, with over 2,000 racially and ethnically diverse biopsied men recruited in the US and Canada, were presented...at the ASCO-GU (The American Society of Clinical Oncology – Genitourinary Cancer Symposium) conference in San Francisco on January 26. The study found that use of the blood-based biomarker Stockholm3 was more accurate and could avoid up to half of unnecessary biopsies compared to current clinical practice. The findings were similar across all racial and ethnic groups."

"A3P Biomedical AB...and BioAgilytix, a global bioanalytical services provider, have entered a partnership with the aim of introducing Stockholm3, as a Lab Developed Test (LDT) designed to redefine the standard of care for early detection of prostate cancer in the USA."